Featured Research

from universities, journals, and other organizations

Pathological thickening of the cardiac wall halted

Date:
March 26, 2013
Source:
Max-Planck-Gesellschaft
Summary:
The heart responds to the increased stress caused by chronically raised blood pressure, for example, by thickening its wall muscle. In the late stage of this condition, a risk of heart failure arises. Scientists have now succeeded in identifying a key molecule in the molecular signalling cascade responsible for this growth. Based on this discovery, they managed to achieve a significant reduction in cardiac wall thickening in animal experiments. In addition, they managed to partly reduce existing thickening of the cardiac wall.

The heart responds to the increased stress caused by chronically raised blood pressure, for example, by thickening its wall muscle. In the late stage of this condition, a risk of heart failure arises. Scientists from the Max Planck Institute for Heart and Lung Research have now succeeded in identifying a key molecule in the molecular signalling cascade responsible for this growth. Based on this discovery, they managed to achieve a significant reduction in cardiac wall thickening in animal experiments. In addition, they managed to partly reduce existing thickening of the cardiac wall.

Related Articles


The heart reacts to intensive, long-term stress by increasing its muscle mass. In competitive athletes, this thickening of the cardiac wall is known as athletic heart syndrome or "athlete's heart." Whereas in this case, the process is a reversible physiological reaction to physical activity, in other cases, cardiac wall thickening, known medically as cardiac hypertrophy, is a serious condition; its progression frequently leads to death through heart failure. The triggers for this pathological change can include, for example, high blood pressure, arteriosclerosis and cardiac valve defects.

Scientists from the Max Planck Institute for Heart and Lung Researchin Bad Nauheim have now identified a crucial interface in the signalling cascade that controls the emergence of cardiac hypertrophy at molecular level. The interface in question is a molecule called RhoGEF12. The crucial indicator was revealed to the researchers in studies on mice, in which the aorta had been artificially narrowed, thereby triggering the development of hypertrophy. "We observed a clear increase in RhoGEF12 activation in the cardiac muscle cells of these mice, " said Nina Wettschureck, who carried out the study in collaboration with Mikito Takefuji. The Max Planck researchers then used genetically modified mice in which RhoGEF12 could be switched off in cardiac muscle cells in their hypertrophy model. "Four weeks after the beginning of the treatment, the cardiac wall thickening in these mice was clearly less advanced than in animals with RhoGEF12," explains Wettschureck. In addition, the heart pump output of the mice without RhoGEF12 was considerably better than that in the control group. This led to a higher survival rate in the long term.

An answer to the question as to whether existing hypertrophy can be reversed by switching off RhoGEF12 was important from a clinical perspective. The Bad Nauheim researchers therefore also investigated this possibility. And in fact, a partial reduction of the thickening was observed in mice with existing cardiac hypertrophy in which RhoGEF12 was switched off. "We believe that RhoGEF12 is so important for the hypertrophy reaction because it combines signals from stretch and hormone receptors," said Wettschureck.

The aim now is to develop a specific therapeutic process based on the insights gained from the study. Wettschureck's group is thus currently investigating the question as to whether the molecular correlations discovered in the study are completely transferable to humans. Should this be confirmed, the next step should lead to the clinical application of the findings. Wettschureck is optimistic: "Two inhibitors have recently become known, which present possible candidates for a therapy. They could provide a basis for a pharmacological approach." Another observation made by the study should also prove helpful in terms of developing a new therapeutic approach: the switching off of RhoGEF12 had no side effects in healthy mice.


Story Source:

The above story is based on materials provided by Max-Planck-Gesellschaft. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. Takefuji, M. Kruger, K. K. Sivaraj, K. Kaibuchi, S. Offermanns, N. Wettschureck. RhoGEF12 controls cardiac remodeling by integrating G protein- and integrin-dependent signaling cascades. Journal of Experimental Medicine, 2013; DOI: 10.1084/jem.20122126

Cite This Page:

Max-Planck-Gesellschaft. "Pathological thickening of the cardiac wall halted." ScienceDaily. ScienceDaily, 26 March 2013. <www.sciencedaily.com/releases/2013/03/130326100848.htm>.
Max-Planck-Gesellschaft. (2013, March 26). Pathological thickening of the cardiac wall halted. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2013/03/130326100848.htm
Max-Planck-Gesellschaft. "Pathological thickening of the cardiac wall halted." ScienceDaily. www.sciencedaily.com/releases/2013/03/130326100848.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins